TGA Opens Door to Faster AI Medical Device Updates

Australia's Therapeutic Goods Administration opened consultation on April 10, 2026, seeking industry feedback on draft guidance for predetermined change control plans, a mechanism designed to accelerate how AI-enabled and software-based medical devices evolve after market approval. The consultation, running until June 5, 2026, targets a core regulatory challenge: traditional approval processes move too slowly for rapidly iterating software. PCCPs allow manufacturers to gain pre-market regulatory acceptance for planned software modifications before implementation, eliminating the need for a separate submission each time a specified change occurs. The framework applies to standalone software classified as a medical device, embedded software controlling other devices, and in vitro diagnostic software

Higher-risk products, particularly those incorporating AI or machine learning with iterative updates or model retraining, stand to benefit most

Under the proposed guidance, manufacturers document planned changes in detail, specify validation and verification methods, and establish impact assessments. Once a PCCP is accepted, manufacturers notify the TGA when a change is implemented rather than triggering a new submission, provided changes remain within pre-defined, low-risk boundaries. Post-market monitoring requirements remain unchanged, and clinical evidence obligations are preserved throughout

The TGA's approach aligns with international standards developed by the International Medical Device Regulators Forum and reflects its technology-agnostic regulatory philosophy: software is regulated by intended purpose, not underlying technology. Quality system controls, device change record retention, and ongoing performance monitoring remain mandatory across the device lifecycle. The consultation signals Australia's intent to maintain alignment with global regulatory frameworks while creating the headroom that adaptive AI products require